Sandesh Seth, Chairman of Actinium Pharmaceuticals Inc (ATNM), says the company is poised to achieve fast-track status with the FDA.
“We are not the fifth me-too drug candidate for a chronic disease. Rather, Iomab-B and Actimab-A — if approved — would have life-extending benefits, and in so doing, Actinium Pharmaceuticals can make a difference,” Seth says. “That really motivates us.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Seth says Iomab-B, Actinium’s drug for patients who cannot withstand chemotherapy, is preparing to enter a Phase III pivotal trial. So far, he says, the drug has demonstrated strong results.
“Iomab-B has shown strong clinical trials results in more than 250 patients to date. In the Phase I/II clinical trials, it has shown that 100% of these patients were able to move to a bone marrow transplant with one-year survival of approximately 30% and two-year survival of approximately 19%, which compares to 10% and 0%, respectively,” Seth says.
Meanwhile, Seth says Actinium expects to have early results in December for its second drug candidate, Actimab-A, which is for elderly patients who are newly diagnosed with AML. Seth says that as a second-generation product, he believes Actimab-A is derisked.
“The first-generation product, Bismab-A, had proof of concept in a Phase I/II study in a tougher patient population, which are relapsed and refractory patients, whereas these are newly diagnosed AML patients…The first-generation product was commercially unviable because it cost $98,000 a dose and had a 46-minute half-life,” Seth says. “We can make the second-generation drug, Actimab-A, which is 500 times more potent for under $10,000, and it is commercially viable with a half-life of 10.5 days, so the logistics work.”
SunTrust Robinson Humphrey Aerospace and Defense Equity Analyst Sees Fast Track to Growth in Small Cap Military Supply Chain
October 01, 2018
Fidelity National Information Services (NYSE:FIS) Likely to Achieve 2016 Expectations
April 14, 2016
Vertex Pharmaceuticals Incorporated (VRTX) on Track to Take Hold in Cystic Fibrosis Market
January 26, 2015
Arena Pharmaceuticals’ (ARNA) Weight-Loss Drug Approved by FDA; 3% Weight Loss Recorded
May 03, 2013
Equinix Inc (EQIX) on Track for 2015 REIT Conversion
September 23, 2013
